WINDTREE THERAPEUTICS INC /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-05-15
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 0.00 shares.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 0.00 shares.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was -862.00K shares, a 43200.00% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 213.00K shares, a 1083.33% increase from fiscal 2022.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 18.00K shares, a 98.89% decline from fiscal 2021.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 1.62M shares, a 188.43% increase from fiscal 2020.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 562.00K shares, a 50.96% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | 0.00 shares derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | 213.00K shares 10-K · filed 2024-04-16 | ||
| 2023-09-30 | 213.00K shares 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | -862.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -862.00K shares derived: sum of 2 quarters · filed 2023-03-31 | -817.00K shares derived: sum of 3 quarters · filed 2023-03-31 | 18.00K shares 10-K · filed 2023-03-31 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 45.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 880.00K shares 10-Q · filed 2022-11-14 | 882.00K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 45.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 880.00K shares 10-Q · filed 2022-08-11 | 882.00K shares derived: sum of 3 quarters · filed 2022-08-11 | 1.13M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 835.00K shares 10-Q · filed 2022-05-05 | 837.00K shares derived: sum of 2 quarters · filed 2022-05-05 | 1.09M shares derived: sum of 3 quarters · filed 2022-05-05 | 1.12M shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 2.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 253.00K shares derived: sum of 2 quarters · filed 2022-03-31 | 282.00K shares derived: sum of 3 quarters · filed 2022-03-31 | 1.62M shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 251.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 280.00K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.62M shares 10-Q · filed 2021-11-10 | 1.64M shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 29.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 1.37M shares 10-Q · filed 2021-08-05 | 1.39M shares derived: sum of 3 quarters · filed 2021-08-05 | 1.93M shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 1.34M shares 10-Q · filed 2021-05-13 | 1.36M shares derived: sum of 2 quarters · filed 2021-05-13 | 1.90M shares derived: sum of 3 quarters · filed 2021-05-13 | |
| 2020-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 557.00K shares derived: sum of 2 quarters · filed 2021-03-29 | 562.00K shares 10-K · filed 2021-03-29 | |
| 2020-09-30 | 532.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | 537.00K shares 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | 5.00K shares 10-Q · filed 2020-08-14 | |||
| 2019-12-31 | 2.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | 2.00K shares derived: sum of 2 quarters · filed 2020-04-03 | 322.00K shares derived: sum of 3 quarters · filed 2020-04-03 | 1.15M shares 10-K · filed 2020-04-03 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 320.00K shares derived: sum of 2 quarters · filed 2019-11-14 | 1.14M shares 10-Q · filed 2019-11-14 | |
| 2019-06-30 | 320.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | 1.14M shares 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | 824.00K shares 10-Q · filed 2019-05-20 | |||
| 2018-12-31 | 4.34M shares 10-K/A · filed 2019-04-23 | |||
| 2017-12-31 | -781.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17 | -781.00K shares derived: sum of 2 quarters · filed 2018-04-17 | -781.00K shares derived: sum of 3 quarters · filed 2018-04-17 | 41.00K shares 10-K · filed 2018-04-17 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2017-11-14 | 822.00K shares 10-Q · filed 2017-11-14 | 832.00K shares derived: sum of 4 quarters · filed 2017-11-14 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-21 | 822.00K shares 10-Q · filed 2017-08-21 | 832.00K shares derived: sum of 3 quarters · filed 2017-08-21 | 1.59M shares derived: sum of 4 quarters · filed 2017-08-21 |
| 2017-03-31 | 822.00K shares 10-Q · filed 2017-05-15 | 832.00K shares derived: sum of 2 quarters · filed 2017-05-15 | 1.59M shares derived: sum of 3 quarters · filed 2017-05-15 | |
| 2016-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | 772.57K shares derived: sum of 2 quarters · filed 2017-03-31 | 773.00K shares 10-K · filed 2017-03-31 | |
| 2016-09-30 | 762.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 763.00K shares 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | 432.00 shares 10-Q · filed 2016-08-10 | |||
| 2015-12-31 | 185.00K shares 10-K · filed 2016-03-29 | |||
| 2014-12-31 | 1.79M shares 10-K · filed 2015-03-16 | |||
| 2013-12-31 | 1.93M shares 10-K · filed 2014-03-17 | |||
| 2012-12-31 | 1.72M shares 10-K · filed 2014-03-17 | |||
| 2011-12-31 | 1.77M shares 10-K · filed 2014-03-17 | |||
| 2010-12-31 | 20.00K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |